Medtronic has strong 1-year results for drug-coated balloon

IN.PACT AV post-approval study “shows consistency of DCB for AV fistula maintenance”

Sanjay Misra New real-world data from the IN.PACT AV Access post-approval study, demonstrating strong safety and effectiveness outcomes for the IN.PACT AV drug-coated balloon (DCB, Medtronic) in the treatment of arteriovenous fistula (AVF) stenoses in patients with end-stage kidney disease (ESKD) on dialysis. The 12-month outcomes were presented in a late-breaking session at the Society of Interventional Radiology (SIR) annual scientific meeting…

Medtronic has strong 1-year results for drug-coated balloon

The In.Pact AV DCB [Image courtesy of Medtronic]Medtronic (NYSE:MDT) today announced new real-world data from a post-approval study of its In.Pact AV drug-coated balloon (DCB). The IN.PACT AV Access post-approval study demonstrated strong safety and effectiveness for the DCB in the treatment of arteriovenous fistula (AVF) stenoses in patients with end-stage kidney disease on dialysis. The study sought to expand real-world experience through eval…